Molecular Quality Control Market (2026-2036)

The growth of this market is mainly driven by the continuing expansion of molecular diagnostic testing in infectious disease, oncology, and genetic testing, each run of which requires characterized controls to demonstrate analytical validity; accreditation and regulatory requirements that oblige laboratories to run controls, document performance, and investigate deviations; the growth of multiplex syndromic panels, which require controls covering many targets at once; and the decentralization of molecular testing to hospital, regional, and near-patient settings, which multiplies the number of sites operating independent quality control programs. In addition, the shift from manufacturer-supplied kit controls toward independent third-party controls, the growth of molecular oncology and liquid biopsy testing requiring low-level controls, the adoption of quality control data management software and peer-group reporting, and the expansion of accredited laboratory capacity in Asia-Pacific are further supporting the growth of this market.

The Molecular Quality Control Market, also referred to as the molecular diagnostics quality control market, molecular controls market, or nucleic acid testing quality control market, comprises the characterized control materials, calibrators, panels, and associated data management software that clinical laboratories and diagnostic manufacturers use to verify and monitor the performance of molecular assays. The market includes independent third-party controls supplied by manufacturers other than the assay provider; instrument- and assay-specific controls supplied with or for a particular platform; quantitative calibrators and standards used to establish and verify measurement scales; multi-analyte and syndromic panels covering respiratory, gastrointestinal, sexually transmitted, blood-borne, and other target groups; whole-process controls supplied in swab, plasma, or other matrix formats that challenge extraction as well as amplification; and quality control data management and peer-group comparison software. The market covers controls for polymerase chain reaction (PCR) and quantitative PCR, digital PCR, next-generation sequencing, transcription-mediated amplification and other isothermal methods, and hybridization-based assays. The market ecosystem extends from control manufacturers, calibrator and standards producers, and software providers to hospital and reference laboratories, public health laboratories, blood and plasma screening centres, in vitro diagnostic manufacturers, and external quality assessment organizers.

Quality control performs a function that no amount of assay sophistication can replace. A molecular assay reports a result, but only a control of known composition establishes that the assay was performing within specification at the moment the result was generated. Controls challenge the complete analytical process, including extraction, amplification, detection, and interpretation, and they detect the failure modes that matter most in molecular testing, including reagent lot variation, instrument drift, inhibition, contamination, and pipeline or software changes. Because a control must be run with each batch or at a defined frequency, demand is recurring and scales with the number of runs performed rather than with instrument placements alone.

Molecular testing volumes underpin the market. Testing for respiratory and other infectious diseases remains substantially above pre-pandemic levels, multiplex syndromic panels have become routine in many settings, and molecular oncology and genetic testing continue to expand. In the second quarter of 2026, Tempus AI, Inc. reported 31% growth in oncology testing volume and 9,000 molecular residual disease tests, illustrating the growth of molecular oncology and liquid biopsy testing that requires characterized controls in every analytical run. In the second quarter of 2026, Illumina, Inc. reported sequencing instrument revenue of USD 125 million, up 31% year over year, and sequencing consumables revenue of USD 775 million, up 5%, reflecting an expanding installed base of molecular platforms that each require routine quality control. Each additional assay in a laboratory menu, and each additional instrument placed, creates a discrete and continuing quality control requirement.

Accreditation and regulation are the principal reason controls are purchased rather than merely recommended. The College of American Pathologists has aligned its Laboratory Accreditation Program checklists with revised Clinical Laboratory Improvement Amendments (CLIA) requirements that took effect in December 2024, and extended individualized quality control plan eligibility to all microbiology culture media, reflecting the continuing evolution of accreditation expectations that govern how laboratories design and document their quality control programs. Laboratories must establish a quality control strategy for each assay, run controls at a defined frequency, review results against established limits, document deviations and corrective action, and demonstrate all of this during inspection. In the U.S., the Food and Drug Administration final rule on laboratory developed tests was vacated by the U.S. District Court for the Eastern District of Texas in March 2025, and in August 2025 the agency signaled its intention to rescind the rule, leaving laboratory developed tests to be validated and monitored primarily under CLIA requirements and accreditation programs rather than FDA premarket review. With laboratory developed tests validated and monitored primarily under CLIA and accreditation programs, the responsibility for demonstrating continuing analytical performance rests squarely with the laboratory, which sustains demand for controls.

Independent third-party controls have become the preferred approach in many laboratories. A control supplied by the manufacturer of the assay shares its reagents, lot history, and design assumptions, and may therefore fail to reveal a systematic problem; an independent control provides an unbiased assessment of the complete process. Accreditation bodies and professional guidance increasingly favour independent controls, and laboratories running assays from several manufacturers value controls that allow performance to be compared consistently across platforms.

The supplier landscape has consolidated considerably. LGC has built its quality control portfolio through successive acquisitions, including Technopath Clinical Diagnostics, which supplies multi-constituent chemistry and immunoassay controls, and, in December 2024, DiaMex of Heidelberg, Germany, which manufactures third-party serology and molecular quality controls, including its Optitrol range of ready-to-use multimarker controls for clinical laboratories and blood banks across Europe, Asia-Pacific, and Latin America. In the second quarter of 2026, Bio-Rad Laboratories, Inc. reported Clinical Diagnostics segment net sales of USD 399.0 million, up 2.6% year over year, with growth attributed to quality systems, diabetes, and blood typing products, partly offset by lower infectious disease sales, while its Life Science segment declined 4.1% on continuing weakness in the academic research market. Bio-Rad has built its molecular control position partly through the acquisition of Exact Diagnostics, and ZeptoMetrix, a long-established supplier of infectious disease controls, was acquired by Cole-Parmer. Consolidation reflects the attraction of recurring, accreditation-driven revenue and the advantage of broad menus that allow a laboratory to source most of its controls from one supplier.

Regulatory grade is becoming a differentiator. In the European Union, the In Vitro Diagnostic Regulation continues to phase in, with manufacturers of Class C self-declared devices required to sign a written agreement with a notified body by September 26, 2026 in order to continue placing legacy devices on the market until the end of 2028, and extended transition timelines running to the end of 2027, 2028, and 2029 for devices that meet the conditions set in the Regulation. Controls supplied for diagnostic use in Europe must meet the Regulation requirements applicable to them, and in vitro diagnostic manufacturers require controls with documented characterization and traceability to support technical documentation. This is driving demand for controls manufactured under quality systems with full documentation rather than research-grade materials repurposed for clinical use.

The market includes dedicated quality control manufacturers and diagnostics companies such as LGC through LGC Clinical Diagnostics, Bio-Rad Laboratories, Thermo Fisher Scientific through its AcroMetrix portfolio, Microbiologics, ZeptoMetrix under Cole-Parmer, Maine Molecular Quality Controls, Randox Laboratories, Revvity through Horizon Discovery, Streck, and Qnostics. These companies compete on menu breadth, commutability with patient samples, whole-process challenge, lot-to-lot consistency, stability and shelf life, matrix and format options, regulatory grade, peer-group data and software, and price per determination.

At the same time, the market faces challenges, including the use of residual patient samples and in-house pooled material in place of commercial controls, cost pressure in laboratories operating under constrained reimbursement, the difficulty of producing controls that behave like genuine clinical specimens, the short notice on which assay and panel content changes, and the absence of fully harmonized expectations for how molecular quality control should be designed. As a result, companies that combine broad menus, demonstrated commutability, whole-process formats, regulatory-grade manufacturing, and useful peer-group data are expected to capture the largest share of growth over the forecast period.